Gaya Pharma, Africa's leading full-service Contract Research Organization (CRO), proudly announces the official launch of its new subsidiary Gaya Pharma CI, based in Abidjan. This strategic milestone marks a decisive step in our mission to advance clinical research, drive real-world evidence (RWE) generation, and expand patient access to innovative therapies across West Africa.
Côte d'Ivoire: A Strategic Hub for West Africa
Côte d'Ivoire has positioned itself as one of the most dynamic healthcare and research ecosystems in the region. By establishing Gaya Pharma CI, we are strengthening our footprint in West Africa to better serve patients, institutions, and pharmaceutical partners in Côte d'Ivoire, Senegal, Mali, Ghana, and beyond.
Driving Real-World Evidence (RWE) Studies in Africa
One of the key missions of Gaya Pharma CI is to lead the development of RWE studies in West Africa. By capturing data from routine clinical practice and patient registries, we aim to:
- Evaluate treatment outcomes in real-world African settings.
- Measure the effectiveness and safety of innovative therapies.
- Support payers and regulators in health technology assessments.
- Provide pharmaceutical partners with evidence to guide market access strategies.
RWE studies will not only advance science but also bridge the gap between innovation and accessibility, ensuring that therapies are adapted to the realities of African healthcare systems.
Looking Ahead
The launch of Gaya Pharma CI is more than an expansion—it is a long-term investment in Africa's health future. By combining clinical research excellence, advanced digital solutions, and patient-focused programs, we are paving the way for stronger research ecosystems.